Ibuprofen 400 mg is effective in women, and women are well represented in trials by Barden, Jodie et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Anesthesiology
Open Access BMC Anesthesiology  2002,  2 x Research article
Ibuprofen 400 mg is effective in women, and women are well 
represented in trials
Jodie Barden1,2, Jayne E Edwards1,2, R Andrew Moore*1,2 and 
Henry J McQuay1,2
Address: 1Pain Research and Nuffield Department of Anaesthetics, University of Oxford Oxford Radcliffe Hospital, The Churchill, 
Headington, Oxford, OX3 7LJ, UK and 2These authors contributed equally to this work
E-mail: Jodie Barden - jodie.barden@pru.ox.ac.uk; Jayne E Edwards - jayne.edwards@pru.ox.ac.uk; R 
Andrew Moore* - andrew.moore@pru.ox.ac.uk; Henry J McQuay - henry.mcquay@pru.ox.ac.uk
*Corresponding author
Abstract
Background:  A recent article in the New Scientist argued that women were under-
represented in clinical trials which, until now, had masked the finding that ibuprofen 400 mg
was ineffective in women.
Methods:  Meta-analysis of randomised, double-blind placebo-controlled trials of ibuprofen
400 mg in acute pain, and use of individual patient information were planned to test the
hypothesis that ibuprofen is ineffective in women. For each trial the proportion of women
participating, the number of patients with at least 50% pain relief and the overall event rate for
ibuprofen 400 mg and placebo was calculated. For each patient percentage pain relief was
calculated, and the numbers of women and men achieving at least 50% pain relief used to calculate
number-needed-to-treat (NNT) for ibuprofen 400 mg compared to placebo.
Results:  Thirty-seven included trials had 3,577 patients, 67% of whom were women. The
proportion with at least 50% pain relief was unaffected by how many women were included. In
an analysis of 678 individual patients the proportion of women and men with at least 50% pain relief
was the same, NNT 3.4 (2.6 to 4.6) and 2.5 (2.0 to 3.3) respectively.
Conclusion: There is no clinically meaningful difference in the efficacy of ibuprofen 400 mg
between men and women experiencing moderate to severe postoperative pain and women
were well represented.
Background
One of us (JB) was told by a chiropractor that ibuprofen
was ineffective in women, implying that there was little
point taking it. This was based on an article in the New
Scientist in January 2002 [1] written by a science writer in
residence at the Novartis Foundation. A single study of ex-
perimental pain in 10 women and 10 men was the source
of the assertion that ibuprofen was ineffective in women
[2], supported by the claim that this was clinical impor-
tant: "This is very dramatic, and has a direct impact for the
clinic". A further assertion was that women were under-
represented in clinical trials of analgesics, which was why
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clinical trials had failed to show the ineffectiveness of ibu-
profen. The article failed to mention that recent clinical re-
search from the Food and Drug Administration found no
gender difference in response rates for ibuprofen in 195
women and 119 men undergoing third molar removal
[3].
Our chiropractor was unaware that JB was updating a
Cochrane review [4] of ibuprofen in acute pain [5], and
that she knew that both assertions were likely to be incor-
rect based on evidence from over 5,000 patients in clinical
comparisons of ibuprofen and placebo. We set out to use
the information from the updated systematic review to ex-
amine gender differences by analysing clinical trials and
individual patient data, and to investigate whether wom-
en have been under-represented in clinical trials of ibu-
profen.
Methods
Published clinical trials
Search strategy and methods of analysis have been pub-
lished previously [4,5]. Randomised, double-blind trials
were sought that compared ibuprofen and placebo in
adult patients with moderate or severe postoperative pain.
Trials had to use conventional pain measurement meth-
ods from which the outcome of at least 50% pain relief
over four to six hours could be obtained [6]. For each trial
the proportion of women participating, the number of pa-
tients with at least 50% pain relief and the overall event
rate for ibuprofen 400 mg and placebo was calculated.
Number-needed-to-treat for men and women separately
could not be calculated from these trials because they did
not report these results by gender.
Individual patient data
Information on 678 individual patients was available
from five randomised, controlled trials comparing ibu-
profen 400 mg with placebo [7]. All trials used identical
criteria and efficacy measures [6] and were assessed using
the same techniques as the clinical trials. For each patient
percentage pain relief was calculated, and the numbers of
women and men achieving at least 50% pain relief used to
calculate number-needed-to-treat for ibuprofen 400 mg
compared to placebo [8]. The z score was used to deter-
mine whether there was a significant difference in the
NNT between women and men [9].
Results
Published clinical trials
Forty nine randomised, double-blind comparisons of
ibuprofen 400 mg and placebo with 4,703 patients
were available. Seven trials were excluded as they failed
to provide details of the number of women and men
participating within each treatment arm. The five trials
with individual patient data were also excluded in order
not to duplicate their results within this analysis. That
left 37 trials with 3,577 patients, of whom 67% were
women (additional file 1). The 37 included studies
were of generally high reporting quality (quality scores
between 2 and 5, median 4 [10]), known to be associated
with minimal reporting bias [11,12].
There were no included trials with fewer than 45%
women. Thirty-two of the 37 trials had more than 50%
women, and 86% of patients were in trials in which
over half the patients were women. Eight trials enrolled
only women (647 women), and no trial enrolled only
men.
The proportion of patients with at least 50% pain relief
from ibuprofen 400 mg (Figure 1) and placebo (Figure 2)
was unaffected by the proportion of women included in
the trials. The event rates for ibuprofen 400 mg varied be-
tween 18% and 85%, a large but expected variation [13].
In the five trials with the lowest proportion (between 45%
and 50%) of women the event rate for ibuprofen 400 mg
was between 39% and 84%. In the eight trials that includ-
ed only women the event rate was between 31% and 75%.
Individual patient data
Here, 57% (192/339) of patients treated with ibuprofen
400 mg were women and 63% (214/339) of patients
treated with placebo were women (additional file 1).
Figure 1
Proportion of patients with at least 50% pain relief
with ibuprofen 400 mg according to the percent-
age of women in the trial. Scatter plot showing the
proportion of patients with at least 50% pain relief over 4–
6 hours following a single dose of ibuprofen 400 mg in
relation to the percentage of women participating in indi-
vidual published clinical trials included in the meta-analysis.
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The number-needed-to-treat for at least 50% pain relief
over four to six hours for women was 3.4 (2.6 to 4.6),
not significantly different than that for men of 2.5 (2.0
to 3.3) (z score 1.58, p = 0.11).
The distribution of the percentage of pain relief experi-
enced by individual patients from ibuprofen 400 mg
and placebo was the same for both women (192 treated
with ibuprofen, 214 with placebo) and men (147 treat-
ed with ibuprofen, 125 with placebo) (Figure 3 and Figure
4).
Discussion
We found no evidence that women have been under-
represented in clinical trials of ibuprofen 400 mg be-
cause two thirds of all patients were women. There was
no difference in the amount of analgesia experienced by
women and men following a single dose of ibuprofen
400 mg. If ibuprofen was without effect in women, tri-
als with a larger proportion of women participating
would show less effect than those with a smaller pro-
portion. Analysis of 37 trials with 3,577 patients
showed no relationship between the proportion of pa-
tients with 50% pain relief and the proportion of wom-
en included in the trials (Figure 1 and 2). Analysis of
individual patient data confirmed this finding, with no
significant difference between the NNT for women and
the NNT for men or in the overall distribution of pain
relief (Figure 3 and Figure 4).
This review includes only 'postoperative' pain trials, a
term under which dental, orthopaedic, abdominal, and
gynaecological surgery, cesearean section and episioto-
my were included. It could be argued that as some of
these procedures occur only in women, confounding by
procedure and gender would be possible. No evidence
of any difference was found for aspirin [14] and a review
of primary dysmenorrhoea reported that pain was effec-
tively treated with ibuprofen with an NNT of 2.6 (2.2 to
3.2) [15]. Studies of ibuprofen in arthritis in which the
majority of patients were women showed no gender-spe-
cific differences in efficacy [16,17].
The important point is the way science is reported, and
the disservice that such 'scare' stories can do. A tiny ex-
perimental pain study, whose results fly in the face of a
wealth of clinical data, was used to score political points
about gender. The result of such publicity could be to
stop women using an effective therapy for pain. The
mass of clinical data here shows that the story was
wrong and hopefully will redress the balance. A mexi-
can-wave effect of rumour-based medical reporting will
always frustrate the careful collection and application of
evidence.
Conclusions
There is no evidence of gender bias in this clinical re-
search or of any clinically meaningful difference in the
efficacy of ibuprofen 400 mg between women and men.
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Figure 3
Spectrum of pain relief with ibuprofen 400 mg for
women and men. Distribution of pain relief (%maxTOT-
PAR) experienced by women and men following ibuprofen
400 mg.
  0-9   10-19  20-29  30-39  40-49  50-59  60-69  70-79  80-89  90-99 100
0
10
20
30
40
50
60
70
80
Percent
%maxTOTPAR
32
20
8
3 4
7
4
7
4
10 9 7
14 16
12
16
8 10
5 5
1 0
Women MenBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/6
Page 4 of 4
(page number not for citation purposes)
from pharmaceutical companies related to analgesics
and other healthcare interventions. All authors have re-
ceived research support from charities, government and
industry sources at various times, but no such support
was received for this work. No author has any direct
stock holding in any pharmaceutical company.
Authors' contributions
JB and RAM argued over the importance of this topic,
and eventually agreed that it had to be sorted. JB updat-
ed the Cochrane review of ibuprofen with supervision
and assistance from JE. JB, RAM and JE analysed data. JB
and RAM drafted a manuscript, which all authors read,
discussed, altered, drafted again, and finally agreed.
Acknowledgements
The work was supported by Pain Research Funds, and the Oxford Pain 
Relief Trust.
References
1. Melton L: His pain, her pain. New Scientist 2002, 2326:32-6
2. Walker J, Carmody J: Experimental pain in healthy human
subjects: gender differences in nocioception and in re-
sponse to ibuprofen. Anesth Analg 1998, 86:1257-62
3. Averbuch M, Katzper M: A search for sex differences in re-
sponse to analgesia. Arch Intern Med 2000, 160(22):3424-8
4. Barden J, Edwards JE, Collins SL, Moore RA, McQuay HJ: Single
oral dose ibuprofen for postoperative pain.  Cochrane Data-
base Syst Rev 
5. Collins SL, Moore RA, McQuay HJ, Wiffen PJ, Edwards JE: Single
dose oral ibuprofen and diclofenac for postoperative pain.
Cochrane Database Syst Rev 2000, 2:CD001548
6. McQuay HJ, Moore RA: An evidence-based resource for pain
relief. Oxford: Oxford University Press 1998
7. Edwards JE, McQuay HJ, Moore RA: Combination analgesic ef-
ficacy: Individual patient data meta-analysis of single dose
oral tramadol plus acetaminophen in acute postoperative
pain. J Pain Symptom Manage 2002, 23(2):121-30
8. Cook RJ, Sackett DL: The number needed to treat: a clinical-
ly useful measure of treatment effect.  Br Med J 1995,
310:452-4
9. Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ: Impact of
covert duplicate publication on meta-analysis: a case
study. Br Med J 1997, 315:635-9
10. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of
reports of randomized clinical trials: is blinding necessary?
Control Clin Trials 1996, 17:1-12
11. Khan KS, Daya S, Jadad AR: The importance of quality of pri-
mary studies in producing unbiased systematic reviews.
Arch Intern Med 1996, 156:661-6
12. Moher D, Pham B, Jones A, et al: Does quality of reports of ran-
domised trials affect estimates of intervention efficacy re-
ported in meta-analyses?. Lancet 1998, 352(9128):609-13
13. McQuay HJ, Carroll D, Moore A: Variation in the placebo ef-
fect in randomised controlled trials of analgesics: All is as
blind as it seems. Pain 1996, 64(2):331-5
14. Edwards JE, Oldman A, Smith L, et al: Oral aspirin in postoper-
ative pain: a quantitative systematic review.  Pain 1999,
81:289-97
15. Zhang WY, Li Wan Po A: Efficacy of minor analgesics in pri-
mary dysmenorrhoea: a systematic review.  Br J Obstet Gy-
naecol 1998, 105:780-9
16. Day R, Morrison B, Luza A, et al: A randomized trial of the ef-
ficacy and tolerability of the COX-2 inhibitor rofecoxib vs
ibuprofen in patients with osteoarthritis.  Arch Intern Med
2000, 160:1781-87
17. Saag K, van der Heijde D, Fisher C, et al: Rofecoxib, a new cy-
clooxygenase 2 inhibitor, shows sustained efficacy, compa-
rable with other nonsteroidal anti-inflammatory drugs.
Arch Fam Med 2000, 9:1124-34
Pre-publication history
The pre-publication history for this paper can be ac-
cessed here:
http://www.biomedcentral.com/1471-2253/2/6/pre-
pub
Figure 4
Spectrum of pain relief with placebo for women
and men. Distribution of pain relief (%maxTOTPAR)
experienced by women and men following placebo.
Additional material
Additional file 1
Details of included studies
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2253-2-6-S1.pdf]
  0-9   10-19  20-29  30-39  40-49  50-59  60-69  70-79  80-89  90-99 100
0
10
20
30
40
50
60
70
80
Percent
%maxTOTPAR
77 77
6 4 3 1 3 5
0 1 3 5 3 4 4
1 1 2 0 1 0 0
Women Men
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com